Another influential voice takes Bristol-Myers’ top execs to task as they scramble to shore up the big Celgene buyout
Brad Loncar is not a big fan of the executive teams at either Bristol-Myers Squibb or Celgene.
Today, as Bristol-Myers scrambled to win investors’ backing, the Loncar Cancer Immunotherapy ETF outlined why it would line up with the growing — though still marginal — opposition that has gathered around the mega-buyout since Wellington, with 8% of Bristol’s shares, said it would be voting against the deal. Loncar joins the activists at Starboard Value who have planted their flag with the rebellion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
